What's in Istituto Oncologico Veneto IRCCS's pipeline?

Istituto Oncologico Veneto IRCCS has 5 drugs in our index: 1 marketed, 0 filed, 1 in Phase 3, 3 in Phase 2, 0 in Phase 1.

Which companies overlap with Istituto Oncologico Veneto IRCCS's portfolio?

Top competitors by shared drug class: CancerVax Corporation, Centre Leon Berard, Chiang Mai University, Chiltern Pesquisa Clinica Ltda, GERCOR - Multidisciplinary Oncology Cooperative Group.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/istituto-oncologico-veneto-irccs.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Istituto Oncologico Veneto IRCCS — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Istituto Oncologico Veneto IRCCS pipeline: 1 marketed, 0 filed, 1 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 3 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Local Standard of Care	Local Standard of Care	marketed			Oncology
MSB0010718C	MSB0010718C	phase 3	Therapeutic cancer vaccine	Patient-specific tumor neoantigens	Oncology

Therapeutic area mix

Oncology · 4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

CancerVax Corporation · 1 shared drug class
Centre Leon Berard · 1 shared drug class
Chiang Mai University · 1 shared drug class
Chiltern Pesquisa Clinica Ltda · 1 shared drug class
GERCOR - Multidisciplinary Oncology Cooperative Group · 1 shared drug class
Galena Biopharma, Inc. · 1 shared drug class
Genocea Biosciences, Inc. · 1 shared drug class
GlaxoSmithKline · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Istituto Oncologico Veneto IRCCS:

Cite this brief

Drug Landscape (2026). Istituto Oncologico Veneto IRCCS — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/istituto-oncologico-veneto-irccs. Accessed 2026-05-17.